Medigen begins making its vaccineBy Kao Shih-ching / Staff reporterMedigen Vaccine Biologics Corp (高端疫苗) on Tuesday said it has begun manufacturing its experimental COVID-19 vaccine, which it hopes to offer once it obtains an emergency use authorization (EUA). An employee works in a Medigen Vaccine Biologics Corp laboratory at the Hsinchu Biomedical Science Park on June 9 last year. Medigen tested three doses of its vaccine — low, medium and high — in the phase 1 trials, with the medium dose showing the best potential, so the phase 2 trials only use the medium dose, he said. Medigen has not found serious adverse reactions or vaccine-associated enhanced diseases among participants in the phase 2 trials, it said. An independent data monitoring committee said that its candidate is safe at a meeting on May 8, Medigen said.

Source: Taipei Times May 19, 2021 15:56 UTC